Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07876960
Recruiting Not applicable

Effects of Virtual Reality Exergames Versus Spinal Manipulation in Chronic Nonspecific Low Back Pain

NCT07876960 · tracked via the Priya Life Science Egypt tracker
Sponsor
Cairo University
Phase
Not applicable
Started
2026-10-01
Last updated
2026-10-15

Condition(s) studied

Chronic Nonspecific Low-back PainCNSLBP

Investigational drug(s) / intervention(s)

Virtual RealitySpinal manipulation

Virtual Reality: The participants will receive a single session of VR Exergames

Spinal manipulation: The participants will receive a single session of spinal manipulation

Study summary

The goal of this clinical trial is to compare the acute effects of virtual reality exergames (VR-EXG) and spinal manipulation on pain, kinesiophobia, mood states, functional disability and lumbar range of motion in individuals with chronic nonspecific low back pain.

The main questions it aims to answer are:

* Does a single session of VR-EXG affect pain, kinesiophobia, mood states, functional disability and lumbar range of motion in individuals with chronic nonspecific low back pain?
* Does a single session of spinal manipulation affect pain, kinesiophobia, mood states, functional disability and lumbar range of motion in individuals with chronic nonspecific low back pain?
* Is there a difference between VR-EXG and spinal manipulation in their acute effects on pain, kinesiophobia, mood states, functional disability and lumbar range of motion?

Researchers will compare participants receiving VR-EXG with those receiving spinal manipulation to determine whether one intervention produces greater acute improvements in pain, kinesiophobia, mood states, functional disability and lumbar range of motion.

Participants will be divided into two groups to be compared: the first group will receive virtual reality exergaming (VR-EXG), while the second group will receive spinal manipulation.

Eligibility

Sex
ALL
Min age
20 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 20-55 years * Chronic nonspecific low back pain lasting at least 3 months. * Pain intensity of ≥3/10 on the VAS at baseline. * Ability to understand and follow the instructions and complete the VR-EXG and spinal-manipulation procedures. * Ability to perform the required lumbar movements. Exclusion Criteria: * Specific spinal pathology, including fracture, spinal infection, malignancy, inflammatory/rheumatologic disease, or severe osteoporosis. * Previous lumbar or spinal surgery. * Neurological conditions or progressive neurological deficits, including significant radicular symptoms. * Serious cardiovascular, systemic, or other medical conditions that contraindicate physical exercise or spinal manipulation. * Pregnancy. * Current acute injury or condition that would prevent safe participation in VR-EXG or spinal manipulation. * Previous adverse reaction or contraindication to spinal manipulation. * Vestibular disorders, severe dizziness, or other conditions that could interfere with safe VR use. * Significant visual or auditory impairment that prevents participation in the VR intervention. * Inability to understand or perform the intervention or outcome assessments. * Use of analgesic medication within 48 hours before assessment/intervention.

Primary outcome measure(s)

  • Pain intensity measured using the visual analogue Scale (VAS) — Pre-intervention, immediately post-intervention and follow up (1 week post-intervention).
    To evaluate the acute effect of the intervention on pain intensity. Scores range from 0 (no pain) to 10 ( worst pain).

Trial sites (1)

FacilityCityRegionStatus
Cairo University Hospitals Giza Giza Governorate Recruiting

More Cairo University trials in Egypt

The Link Between Periodontitis, Smoking and Oral Cancer Starting soon
Treating Intrabony Defect With MINST VS MINST Extended PRF Recruiting
Respiratory Exercises Versus Deep Neck Flexor Training in Chronic Mechanical Neck Pain Recruiting
Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure Starting soon
Preparation Time Of Bioflx Crowns Compared To Zirconia Crowns On Primary Molars Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07876960 on ClinicalTrials.gov ↗ ← All trials in Egypt